Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181 is registered in ClinicalTrials.gov with Jonathan Santoro as lead sponsor.

NCT NCT07812181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
Lead sponsor
Jonathan Santoro
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 1, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome (trisomy 21), down syndrome regression disorder (dsrd), neuroinflammatory / neuropsychiatric disorder